SCMP - Sucampo Pharmaceuticals, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Moody's2 months ago

    Mallinckrodt International Finance SA -- Moody's downgrades Mallinckrodt's CFR to B1; outlook negative

    This is high in the context of Mallinckrodt's business risks. Further, the company faces a number of headwinds over the next several years including the loss of patent exclusivity on Ofirmev in January 2021 and rising competitive pressures in Mallinckrodt's largest franchises. Absent significant progress in its pipeline, Moody's believes Mallinckrodt will face multiple years of earnings stagnation or declines.

  • We're sorry this is all we were able to find about this topic.